Loading...
Loading...
Also known as: Egrifta, TH9507, GHRH analog
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Benefits
6
Conditions
5
Evidence
Phase 3 trials, FDA approved for HIV lipodystrophy+ studies
Source
Synthetic GHRH analog with trans-3-hexenoic acid modification
Gabriel Brain Score
Strong
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Binds GHRH receptors on pituitary somatotrophs, stimulates pulsatile GH release, increases IGF-1, preferentially reduces visceral fat via GH-mediated lipolysis, minimal effect on subcutaneous fat.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Phase 3 trials, FDA approved for HIV lipodystrophy
FDA approved based on trials showing 15-20% visceral fat reduction. Strong evidence for body composition improvement. Emerging research for cognitive enhancement in mild impairment.
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
Long-acting GHRH analog that stimulates sustained growth hormone release.
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.